The Chlamydia family of human pathogens uses outer envelope proteins that are highly cross-linked by disulfide bonds but nevertheless keeps an unusually high number of unpaired cysteines in its secreted proteins. To gain insight into chlamydial disulfide bond catalysis, the structure, function, and substrate interaction of a novel periplasmic oxidoreductase, termed DsbH, were determined. The structure of DsbH, its redox potential of ؊269 mV, and its functional properties are similar to thioredoxin and the C-terminal domain of DsbD, i.e. characteristic of a disulfide reductase. As compared with these proteins, the two central residues of the DsbH catalytic motif (CMWC) shield the catalytic disulfide bond and are selectively perturbed by a peptide ligand. This shows that these oxidoreductase family characteristic residues are not only important in determining the redox potential of the catalytic disulfide bond but also in influencing substrate interactions. For DsbH, three functional roles are conceivable; that is, reducing intermolecular disulfides between proteins and small molecules, keeping a specific subset of exported proteins reduced, or maintaining the periplasm of Chlamydia in a generally reducing state.Chlamydia are obligate intracellular eubacteria that are phylogenetically distant from other bacterial divisions (1). Virtually every human being will be infected with Chlamydia pneumoniae in their lifetime, and this organism accounts for ϳ10% of pneumonia cases and 5% of bronchitis cases in the United States (2, 3). Acute infections are usually mild in immunocompetent hosts, but severe pneumonias are observed in immunocompromised patients. Chronic C. pneumoniae infections have been associated with arterial disease (4), where C. pneumoniae act to continuously stimulate inflammation and thereby contribute to stroke and coronary heart disease. Chlamydia have an unique developmental cycle in which the extracellular infectious form, the elementary body, is metabolically inactive and highly resistant to lysis. This is thought to be due in large part to a complex of outer envelope proteins that are highly crosslinked by disulfide bonds (5). Disulfide cross-linked envelope proteins appear to substitute for peptidoglycan in the elementary body (6). This is in contrast to the intracellular, non-infectious but metabolically active reticulate body which employs peptidoglycan (7), like other Gram-negative bacteria. The reliance of the elementary body on disulfide bond-linked proteins suggests that interference with chlamydial disulfide bond catalysis offers a potential avenue for treating chlamydial infections in addition to antibiotics administration. Despite the extensive use of disulfide cross-linked envelope proteins, Chlamydia exhibit an unusually high number of unpaired cysteines in their secreted proteins compared with Escherichia coli. Is the machinery for periplasmic disulfide bond catalysis in Chlamydia different from E. coli?Functional gene assignment of the C. pneumoniae TW183 genome predicts 5 periplasmic...

A novel octahedral complex CoII(HAPP)(TFA)2 [hexaazaphenantholine-cyclophane (HAPP), trifluoroacetate (TFA)] is a DNA bulge-specific probe with single-strand DNA cleavage activity in the presence of H2O2. This complex exhibits low affinity towards double-stranded DNA and low reactivity toward single-stranded DNA. Metal-HAPP complexes with different coordination number and ring size were synthesized and their selectivity and reactivity for DNA bulges were compared. The DNA sequence at the bulge site influences the intensity of cleavage at the bulge and the flanking sites after piperidine treatment. Cleavage specificity of CoII(HAPP)(TFA)2 was characterized extensively using scavenger reagents to quench the cleavage reaction and high-resolution polyacrylamide gel electrophoresis. In addition, 3'-phosphoglycolate cleavage products were trapped and analyzed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. These data were used to deduce that the DNA cleavage pathway for CoIIHAPP2+ in the presence of H2O2 involves 4'-H abstraction of the deoxyribose moiety.

Bacteria in the environment play a major role in the degradation of widely used man-made recalcitrant organic compounds. Pseudomonas nitroreducens TX1 is of special interest because of its high efficiency to remove nonionic ethoxylated surfactants. In this study, a novel approach was demonstrated by a bacterial enzyme involved in the formation of radicals to attack ethoxylated surfactants. The dihydrolipoamide dehydrogenase was purified from the crude extract of strain TX1 by using octylphenol polyethoxylate (OPEO n ) as substrate. The extent of removal of OPEOs during the degradation process was conducted by purified recombinant enzyme from E. coli BL21 (DE3) in the presence of the excess of metal mixtures (Mn 2+ , Mg 2+ , Zn 2+ , and Cu 2+ ). The metabolites and the degradation rates were analyzed and determined by liquid chromatography-mass spectrometry. The enzyme was demonstrated to form Fenton reagent in the presence of an excess of metals. Under this in vitro condition, it was shown to be able to shorten the ethoxylate chains of OPEO n . After 2 hours of reaction, the products obtained from the degradation experiment revealed a prominent ion peak at m / z = 493.3, namely the ethoxylate chain unit is 6 (OPEO 6 ) compared to OPEO 9 ( m/z = 625.3), the main undegraded surfactant in the no enzyme control. It revealed that the concentration of OPEO 15 and OPEO 9 decreased by 90% and 40% after 4 hours, respectively. The disappearance rates for the OPEO n homologs correlated to the length of the exothylate chains, suggesting it is not a specific enzymatic reaction which cleaves one unit by unit from the end of the ethoxylate chain. The results indicate the diverse and novel strategy by bacteria to catabolize organic compounds by using existing housekeeping enzyme(s).

No abstract

Background The interaction between the adhesion molecule MAdCAM-1 and the α4β7 integrin heterodimer enables the trafficking of gut-antigen specific lymphocytes to the small and large intestines and to gut-associated lymphoid tissues. The role of the α4β7 integrin in the pathophysiology of IBD has been clinically demonstrated, and targeted therapeutics have been shown to mitigate inflammation and mucosal damage mediated by α4β7+ lymphocytes. The purpose of this study was to determine the potency and selectivity of the small molecule α4β7 inhibitor GS-1069518. Methods The selectivity of GS-1069518 and relevant reference molecules was determined using in vitro cell capture assays with natural integrin ligands and by measuring receptor occupancy in human and cynomolgus monkey whole blood. The number of RPMI-8866 cells binding to MAdCAM-1-coated surfaces (a natural α4β7 ligand) and Jurkat cells binding to VCAM-1-coated surfaces (a natural α4β1 ligand) were quantified with high content imaging. Receptor occupancy on CD3+CD4+CD45RO+β7+ (human) or CD3+CD4+CD45RA-β7+ (cynomolgus monkey) and CD3+CD4+CD45RO+α4+β1+β7- (human) or CD3+CD4+CD45RA-α4+β1+β7- (cynomolgus monkey) memory T cells was measured by flow cytometry with fluorescent probes that detect occupancy in the ligand-binding sites. Results In a MAdCAM-1 cell capture assay, the EC50 of GS-1069518 was 0.034 nM, with 71-fold and >10,000-fold selectivity over α4β1 and αLβ2, respectively. In α4β7 receptor occupancy assays the EC50 of GS-1069518 was 0.36 nM in human whole blood and 0.4 nM in cynomolgus monkey whole blood. GS-1069518 was 482-fold selective for α4β7 over α4β1 in human whole blood and 119-fold selective for α4β7 in cynomolgus monkey blood. Conclusion GS-1069518 is a highly potent and selective small molecule inhibitor of the α4β7-MAdCAM-1 ligand binding interaction.